共 39 条
- [21] Phase I/II first-in-human CAR T-targeting MUC1 transmembrane cleavage product (MUC1*) in patients with metastatic breast cancerJOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Bamdad, Cynthia CarolYuan, YuanSpecht, Jennifer M.Stewart, Andrew K.Smagghe, Benoit J.Lin, Stephen Chi-MinCarter, Mark G.Synold, Timothy W.Frankel, Paul HenryParekh, VishwasWalkley, Danica M.Budde, L. ElizabethLiu-Michael, QingNash, Jac-LeenNash, Michael J.Reale, Laura M.Yi, Kevin Y.Kim, TeresaHamilton, Stanley R.Forman, Stephen J.
- [22] MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-a, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I TrialCLINICAL CANCER RESEARCH, 2020, 26 (15) : 3936 - 3946Sarker, DebashisPlummer, RuthMeyer, TimSodergren, Mikael H.Basu, BristiChee, Cheng EanHuang, Kai-WenPalmer, Daniel H.Ting, YukEvans, T. R. JeffSpalding, Duncan R. C.Pai, MadhavaSharma, RohiniPinato, David J.Spicer, JamesHunter, SarahKwatra, VineetNicholls, Joanna P.Collin, DavidNutbrown, RobertGlenny, HelenFairbairn, SoniaReebye, VikashVoutila, JonDorman, StephanieAndrikakou, PinelopiLloyd, PeterFelstead, SteveVasara, JenniHabib, RobertWood, ChrisSaetrom, PalHuber, Hans E.Blakey, David C.Rossi, John J.Habib, Nagy
- [23] A phase I clinical trial to evaluate the pharmacokinetics, toxicity and dosimetry of 111-indium-labeled human epidermal growth factor in patients with metastatic breast cancerRADIOTHERAPY AND ONCOLOGY, 2005, 76 : S35 - S35Vallis, KReilley, RScollard, DPetronis, JCaldwell, CHendler, ALockwood, GOza, A
- [24] YL202/BNT326, a HER3-targeted ADC, in patients with locally advanced or metastatic non-small cell lung cancer and breast cancer: Preliminary results from a first-in-human phase I trialJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Cheng, YingZhang, XiaochenLiu, JianHuang, ZhangzhouLv, DongqingZhang, YipingWang, XiaojiaChaudhry, ArvindAmin, HarshadDamodaran, SenthilPatel, Shiven B.Assad, HadeelLee, Arielle ShebayZhao, HuiBai, JinyunXue, TongtongChin, Steve
- [25] First-in-human HER2-targeted bispecific antibody KN026 for the treatment of patients with HER2-positive metastatic breast cancer: Results from a phase I studyCANCER RESEARCH, 2022, 82 (04)Zhang, JianJi, DongmeiCai, LiYao, HeruiYan, MinWang, XiaojiaShen, WeinaDu, YiqunPang, HuiLai, XiupingZeng, HuiaiHuang, JianSun, YanPeng, XinxinXu, JunfangYang, JingYang, FeiXu, TingHu, Xichun
- [26] First-in-human phase I clinical trial of NY-ESO-1 protein cancer vaccine with a novel adjuvant MIS416, NOD2 and TLR9 stimulant, for patients with NY-ESO-1 expressing solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Ishihara, MikiyaTono, YasutakaMiyahara, YoshihiroHarada, NaozumiKageyama, ShinichiSasaki, TakeshiHori, YasuhideSoga, NorihitoUchida, KatsunoriShiraishi, TaizoSato, EiichiKanda, HidekiMizuno, ToshiroWebster, GillIkeda, HiroakiKatayama, NaoyukiSugimura, YoshikiShiku, Hiroshi
- [27] First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I StudyCLINICAL CANCER RESEARCH, 2022, 28 (04) : 618 - 628Zhang, JianJi, DongmeiCai, LiYao, HeruiYan, MinWang, XiaojiaShen, WeinaDu, YiqunPang, HuiLai, XiupingZeng, HuiaiHuang, JianSun, YanPeng, XinxinXu, JunfangYang, JingYang, FeiXu, TingHu, Xichun
- [28] Safety, tolerability, and efficacy of the novel intravenous manganese-based contrast agent SN132D in patients with breast cancer: initial results of a Phase I, First-In-Human clinical trial SPAGOPIX-01CANCER RESEARCH, 2023, 83 (05)Warnberg, FredrikKarakatsanis, AndreasShcherbina, LiliyaSjoberg, FolkeHargreaves, PaulCuriac, Ioan-DanJohansson, EdvinAxelsson, OskarHansen, Mats
- [29] First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancerJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2025, 13 (01)Lakhani, Nehal J.Stewart, DaphneRichardson, Debra L.Dockery, Lauren E.Van Le, LindaCall, JustinRangwala, FatimaWang, GuanfangMa, BoMetenou, SimonHuguet, JadeOffman, ElliotPandite, LiniHamilton, Erika
- [30] A phase I clinical trial of ganetespib (heat shock protein 90 inhibitor) in combination with paclitaxel and trastuzumab in human epidermal growth factor receptor-2 positive (HER2+) metastatic breast cancerCANCER RESEARCH, 2015, 75Jhaveri, KomalCadoo, KarenChandarlapaty, SaratTeplinsky, EleonoraSpeyer, JamesD' Andrea, GabriellaPatil, SujataHaque, SofiaFriedman, KentHeese, ScottNeville, DeirdreEsteva, FranciscoHudis, CliffordModi, Shanu